
<!DOCTYPE html>

<html lang="en">
<head>
	<meta charset="utf-8">
	<meta name="viewport" content="width=device-width, initial-scale=1">
	<title></title>
	<link rel="stylesheet" href="css/ge.css" type="text/css" />
	<link rel="stylesheet" href="css/animate.css" type="text/css" />
	<script type="text/javascript" src="js/base.js"></script>
	<script type="text/javascript" charset="utf-8">
		
		var ANIMATION = [];
		
	</script>
</head>
<body class="slide-ref">

<div id="popup" style="width:900px;"> 
<ol>
<li><span>KALETRA [package insert].</span></li>
<li><span>Myers T, Worthington C, Haubrich DJ, et al. HIV testing and counseling: test providers' experiences of best practices. <em>AIDS Educ Prev</em>. 2003;15:309-319.</span></li>
<li><span>Kreps GL, Sparks L. Meeting the health literacy needs of immigrant populations. <br><em>Patient Educ Couns</em>. 2008;71:328-332.</span></li>
<li><span>IMS New-to-Brand data, December 2009-December 2010.</span></li>
<li><span>Murphy RL, da Silva BA, Hicks CB, et al. Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-positive patients. HIV Clin Trials. 2008;9:1-10.</span></li>
<li><span>Gathe J, da Silva BA, Cohen DE, et al. A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily<br>dosing and results in similar safety and tolerability in antiretroviral-naïve subjects through 48 weeks. <span style="position:relative; left:3px;"><em>J Acquir Immune</em></span><br><em>Defic Syndr.</em> 2009;50:474-481.</span></li>
<li><span>Walmsley S, Bernstein B, King M, et al. Lopinavir/ritonavir versus nelfinavir for the initial treatment of HIV infection.<br><em>N Engl J Med</em>. 2002;346:2039-2046.</span></li>
<li><span>Johnson M, Gathe J, Podzamczer D, et al. A Once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. <em>J Acquir Immune Defic Syndr</em>. 2006;43:153-160.</span></li>
<li><span>Zajdenverg R, Podsadecki TJ, Badal-Faesen S, et al. Similar safety and efficacy of once- and twice-daily lopinavir/ritonavir tablets in treatment-experienced HIV-1 infected subjects at 48 weeks. <em>J Acquir Immune Defic Syndr</em>. 2010;54:143-151.</span></li>
<li><span>Data on file, AbbVie Inc.</span></li>


</ol>



</div>

</body>
</html>

